Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013

    Vermillion to Participate in Lazard Capital Markets 5th Annual Medical
             Technology Snowbird Conference on February 27, 2013

PR Newswire

AUSTIN, Texas, Feb. 19, 2013

AUSTIN, Texas, Feb. 19, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML),
a molecular diagnostics company focused on gynecologic cancers and vascular
medicine, has been invited to participate in Lazard Capital Market's 5th
Annual Medical Technology Snowbird Conference. The conference is being held at
the Cliff Lodge Snowbird Ski & Summer Resort in Snowbird, Utah from February
27 - March 1, 2013.

Vermillion's Interim CEO Bruce A. Huebner is scheduled to participate in
one-on-one meetings with institutional investors to be held throughout the day
on Wednesday, February 27, 2013. He will discuss the company's initiatives to
drive market adoption of OVA1®, the first FDA-cleared blood test for the
pre-surgical diagnosis of ovarian masses using a unique multi-marker

For more information about the conference or to schedule a one-on-one meeting
with Vermillion management, contact your Lazard representative.

About Lazard Capital Markets
Lazard Capital Markets is a growth-oriented full service broker-dealer with a
unique position in today's capital markets. The company's institutional
clients value its focused, action-oriented proprietary research, which is
based on deep domain expertise in the Healthcare, Consumer, Energy, Technology
and Transportation sectors. The company's Sales and Trading professionals have
long-standing relationships with over 600 institutional accounts, and, with an
average of 15 years of experience, have an intimate knowledge of our clients'
investment objectives. Finally, the company's relationship with Lazard, an
international investment bank, which operates in 39 cities across 21
countries, provides the company with unparalleled global connections. For more
information, visit

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Vermillion, along with its
prestigious scientific collaborators, has diagnostic programs in oncology,
vascular medicine and women's health. Additional information about Vermillion
can be found at

Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Tel 949-574-3860

SOURCE Vermillion, Inc.

Press spacebar to pause and continue. Press esc to stop.